Hormonal choices after gestational diabetes: Subsequent pregnancy, contraception, and hormone replacement

Diabetes Care

Volumn 21, Issue SUPPL.2, 1998, Pages

  Kjos, Siri L ^a   Peters, Ruth K ^a   Xiang, Anny ^a   Schaefer, Ute ^b   Buchanan, Thomas A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CORONARY ARTERY DISEASE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL CONTRACEPTION; POSTMENOPAUSE; PREGNANCY; PREGNANCY DIABETES MELLITUS;

CONTRACEPTIVES, ORAL; DIABETES MELLITUS, TYPE 1; DIABETES, GESTATIONAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GRAVIDITY; HUMANS; INTRAUTERINE DEVICES, COPPER; PREGNANCY; RISK FACTORS; UNITED STATES;

EID: 2642679227     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (86)

1. O'Sullivan JB, Mahan CM: Criteria for the oral glucose tolerance test in pregnancy. Diabetes 13:278-285, 1964
2. Berkowitz KM, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA: Effect of troglitazone on insulin sensitivity and pancreatic B-cell function in women at high risk for non-insulin-dependent diabetes mellitus. Diabetes 45:1572-1579, 1996
3. O'Sullivan JB: Diabetes after GDM. Diabetes 40 (Suppl. 2):131-135, 1991
4. Mestman JH: Follow-up studies in women with gestational diabetes mellitus: the experience at Los Angeles County/University of Southern California Medical Center. In Gestational Diabetes. Weiss PA, Coustan DR, Eds. New York, Springer-Verlag, 1987, p. 191-198
5. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA: Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes 44:586-591, 1995
6. Damm P, Kohl C, Bertelsmann A, Mølsted-Pedersen L: Predictive factors for the development of diabetes in women with gestational diabetes mellitus. Am J Obstet Gynecol 168:607-616, 1992
7. Henry OA, Beischer NA: Long-term implications of gestational diabetes: long-term implications of gestational diabetes for the mother. Bailliere's Clin Obstet Gynecol 5: 461-482, 1991
8. Pettit DJ, Knowler WC, Baird HR, Bennett PH: Gestational diabetes: infant and maternal complications of pregnancy in relation to third-trimester glucose tolerance in Pima Indians. Diabetes Care 3:458-464, 1980
9. Metzger BE, Cho NH, Roston SM, Rodvany R: Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes. Diabetes Care 16:1598-1605, 1993
10. Cocilovo G, Tomasi F, Guerra S, Zampini A, Cucorullo A: Risk factors associated with persistence of glucose intolerance one year after gestational diabetes. Diabetes Metab 16:187-190, 1990
11. Catalane PM, Virgo KM, Bernstein IM, Amine SB: Incidence and risk factors associated with abnormal glucose tolerance in women with gestational diabetes. Am J Obstet Gynecol 165:914-919, 1991
12. O'Sullivan JB: Body weight and subsequent diabetes. JAMA 248:949-952, 1982
13. Persson B, Hanson U, Hartling SG, Binder C: Follow-up of women with previous GDM: insulin C-peptide and proinsulin responses to oral glucose load. Diabetes 40 (Suppl. 2):136-141, 1991
14. Burchfiel CM, Sharp DS, Curb DJ, Rodriguez BL, Hwang LJ, Marcus EB, Yano K: Physical activity and incidence of diabetes: the Honolulu Heart Program. Am J Epidemiol 141:360-368, 1995
15. Buchanan TA, Metzger BE, Freinkel N, Bergman RN: Insulin sensitivity and β-cell responsiveness to glucose tolerance in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 162:1008-1014, 1990
16. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EH: Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol 165:1667-1672, 1991
17. Spellacy WN, Goetz FC: Plasma insulin in normal late pregnancy. N Engl J Med 268:988-991, 1963
18. Bleicher SJ, O'Sullivan JB, Freinkel N: Carbohydrate metabolism in pregnancy V. The interrelations of glucose, insulin and free fatty acids in later pregnancy and postpartum. N Engl J Med 271:866-872, 1964
19. Pyke DA: Parity and the incidence of diabetes. Lancet 270:818-821, 1956
20. Beral V: Long-term effects of childbearing on health. J Epidemiol Commun Health 39:343-346, 1985
21. Kritz-Silverstein C, Barrett-Connor E, Wingard DL: The effect of parity on the later development of non-insulin-dependent diabetes mellitus or impaired glucose tolerance. N Engl J Med 321:1214-1219, 1989
22. Manson JE, Rimm EB, Colditz GA, Stampher MJ, Willet WC, Arky RA, Rosner B, Hennekens CH, Speizer FE: Parity and incidence of non-insulin-dependent diabetes mellitus. Am J Med 93:13-18, 1992
23. West KM: Epidemiology of Diabetes and Its Vascular Lesions. New York, Elsevier, 1978, p. 221-224
24. Peters RK, Kjos SL, Xiang A, Buchanan TA: Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. Lancet 347:227-30, 1996
25. Dong ZG, Beischer NA, Wein P, Sheedy MT: Value of early glucose tolerance testing in women who had gestational diabetes in their previous pregnancy. Aust N Z J Obstet Gynaecol 33:350-357, 1993
26. Gaudier FL, Hauth JC, Poist M, Corbett D, Cliver SP: Recurrence of gestational diabetes mellitus. Obstet Gynecol 80:755-758, 1992
27. DeFronzo RA: The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
28. Saad MF, Knowler WC, Pettit DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in Pima Indians. N Engl J Med 319:1500-1505, 1988
29. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 29:1039-1057, 1979
30. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985, p. 9-17 (Tech. Rep. Ser., no. 727)
31. Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes. Am J Obstet Cynecol 144:768-773, 1982
32. Parley TMM, Rosenberg MJ, Rowe PJ, Chen J, Meirik O: Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339:785-788, 1992
33. Skouby SO, Mølsted-Pedersen L, Kosonen A: Consequences of intrauterine contraception in diabetic women. Fertil Steril 42:568-572, 1984
34. Kimmerle R, Weiss R, Berger M, Kurz KH: Effectiveness, safety and acceptability of a copper intrauterine device (CT Safe 300) in type I diabetic women. Diabetes Care 16:1227-1230, 1993
35. Kjos SL, Ballagh SA, LaCour M, Xiang A, Mishell DR: The copper T380A intrauterine device in women with type II diabetes mellitus. Obstet Gynecol 84:1006-1009, 1994
36. Spellacy W: Carbohydrate metabolism during treatment with estrogen, progestogen and low-dose oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 142:732-734, 1982
37. Perlman JA, Russell-Briefel R, Ezzati T, Lieberknecht G: Oral glucose tolerance and the potency of contraceptive progestins. J Chronic Dis 338:857-864, 1985
38. Gosland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaouku V, Davenport M, Wynn V: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381, 1990
39. Bringer J: Norgestimate: a clinical overview of a new progestin. Am J Obstet Gynecol 166:1969-1977, 1992
40. Loke DFM, Ng CSA, Samsioe G, Hoick S, Ratnam SS: A comparative study of the effects of a monophasic and triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. Contraception 42:535-554, 1990
41. Peterson KR, Skouby SO, Pedersen RG: Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol 78:666-672, 1991
42. Runnebaum B, Grunwald K, Rabe T: The efficacy and tolerability of norgestimate/ ethinyl estradiol (250 g of norgestimate/35 g of ethinyl estradiol): results of a open, multicenter study of 59,701 women. Am J Obstet Gynecol 166:1963-1968, 1992
43. van der Vage N, Kloosterboer HJ, Haspels AA: Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 156:918-922, 1987
44. Skouby SO, Anderson O, Saurbrey N, Kuhl C: Oral contraception and insulin sensitivity: In vivo assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab, 64:519-523, 1987
45. Skouby So, Kuhl C, Mølsted-Pedersen L, Peterson K, Christensen MS: Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol 153:495-500, 1985
46. Mølsted-Pedersen L, Skouby SO, Damm P: Preconception counseling and contraception after gestational diabetes. Diabetes 40 (Suppl. 2):147-150, 1991
47. Radberg T, Gustafson A, Skryten A, Karlsson K: Metabolic studies in gestational diabetic women during contraceptive treatment: effects on glucose tolerance and fatty acid composition of serum lipids. Gynecol Obstet Invest 13:17-29, 1982
48. Kung AW, Ma JT, Wong VC, Li DF, Ng MM, Wang CC, Lam KS: Glucose and lipid metabolism with triphasic oral contraceptives in women with a history of gestational diabetes. Contraception 35:257-269, 1987
49. Kjos SL, Shoupe D, Douyan S, Friedman RL, Bernstein GS, Mestman JH, Mishell DR Jr: Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. Am J Obstet Gynecol 163:1822-1827, 1990
50. Kjos SL, Peters R, Xiang A, Schaefer U, Buchanan TA: Hormonal contraception is associated with an increased risk of diabetes after gestational diabetes mellitus (Abstract). Diabetes 45 (Suppl. 2):58A, 1996
51. Kjos SL, Henry O, Lee RM, Buchanan TA, Mishell DR Jr: The effect of lactation on glucose and lipid metabolism in women with recent gestational diabetes. Obstet Gynecol 82:451-455, 1993
52. Kalkhoff RK: Metabolic effects of progesterone. Am J Obstet Gynecol 142:735-738, 1982
53. Fahmy K, Abdel-Razik M, Shaaraway M, Al-Kholy G, Saad S, Wagdi A, Al-Azzony M: Effect of long-acting progestogen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 44:419-429, 1991
54. Liew DFM, Ng CSA, Yong YM, Ratnam SS: Long-term effects of depo-provera on carbohydrate and lipid metabolism. Contraception 31:51-64, 1985
55. Konje J, Otolorin EO, Ladipo OA: Changes in carbohydrate metabolism during 30 months of Norplant. Contraception 44:163-172, 1991
56. Singh K, Viegas OAC, Loke DFM, Ratnam SS: Effect of Norplant implants on liver, lipid and carbohydrate metabolism. Contraception 45:141-153, 1992
57. Metzger BE, Coustan DR, the Organizing Committee: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 21 (Suppl. 2):B161-B167, 1998
58. Mills JL, Baker L, Goldman AS: Malformations in infants of diabetic mothers occur before the seventh gestational week: implications for treatment. Diabetes 28:292-293, 1979
59. Hanson U, Persson B, Thunell S: Relationship between hemoglobin A1c in early type I (insulin-dependent) diabetic pregnancy and the occurrence of spontaneous abortion and fetal malformation in Sweden. Diabetologia 33:100-104, 1990
60. Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA: Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. Obstet Gynecol 84:515-520, 1994
61. Towner D, KJOS SL, Leung B, Montoro MM, Xiang A, Mestman JH, Buchanan TA: Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 18:1446-1451, 1995
62. Schaefer UM, Songster G, Xiang A, Berkowitz K, Buchanan TA, Kjos SL: Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy. Am J Obstet Gynecol 177:1165-1171, 1997
63. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037, 1992
64. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990, 1991
65. Grodstein E Stampfer M, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1775, 1997
66. Cummings SR, Black DM, Rubin SM: Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445-2448, 1989
67. Brinton LA, Schairier C: Postmenopausal hormone replacement therapy: time for reappraisal? (Editorial) N Engl J Med 336: 1821-1822, 1997
68. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnidar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204, 1991
69. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation 75:1102-1109, 1987
70. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski VA: Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 115:954-963, 1988
71. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199-208, 1995
72. Manson JE: A prospective study of postparmm oestrogen therapy and subsequent incidence of non-insulin dependent diabetes mellitus. Ann Epidemiol 2:665-673, 1992
73. Gilligan DM, Quyyumi AA, Cannon RO: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2545-2551 1994
74. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in post-menopausal women. Circulation 89:52-60, 1994
75. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P: Beneficial effect of estrogen on exercise induced myocardial eschaemia in women with coronary artery disease. Lancet 342:133-136, 1993
76. McCrohon JA, Adams M, McCredie RJ, Robinson J, Pike A, Abbey M, Keech AC, Celermajer DS: Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol 45:435-441, 1996
77. Manson JE, Colditz GA, Stampher JM, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141-1147, 1991
78. Kannel WB: Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 114:413-419, 1987
79. Sullivan JM, VanderZwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM: Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 150:2557-2562, 1990
80. Robinson JF, Folsom AR, Nabulsi AA, Watson R, Brancati FL, Cai J, for the Athero-sclerosis Risk in Communities Study Investigators: Can postmenopausal hormone replacement improve plasma lipids women with diabetes? Diabetes Care 19:480-485, 1996
81. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. Ann Intern Med 87:393-397, 1977
82. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S: Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 307:1318-1322, 1993
83. Bengtsson, C Bjorkelund C, Lapidus L, Lissner L: Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow-up of participants in a prospective population study in Gothenburg, Sweden. BMJ 307:1385-1388, 1993
84. Criqui MH, Heiss MPH, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, O'Grady HK, Davis CE: Plasma triglyceride levels and mortality from coronary heart disease. N Engl J Med 328:1220-1225, 1993
85. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein and Coronary Heart Disease: Triglyceride, high-density lipoprotein and coronary heart disease. JAMA 269:505-510, 1993
86. Brussaard HE, Gever-Leuven JA, Frolich M, Kluft C, Krans HMJ: Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women. Diabetologia 40:843-849, 1997